World's Best Scientists 2026 revealed!
Byoung Chul Cho

Byoung Chul Cho

D-Index & Metrics

Medicine

D-Index
97
Citations
51184
World Ranking
9094
National Ranking
22

Overview

Byoung Chul Cho is affiliated with Yonsei University in South Korea and has a significant publication record in the field of Medicine, with a primary focus on Oncology and Pulmonary and Respiratory Medicine. Their work extends into Molecular Biology, Cancer Research, and Immunology, reflecting a multidisciplinary approach to cancer studies and treatment development.

The scientist's main research topics include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Diagnosis and Treatment
  • Gastric Cancer Management and Outcomes
  • Cancer Genomics and Diagnostics

Frequent co-authors in their research collaborations are:

  • Min Hee Hong
  • Sun Min Lim
  • Enriqueta Felip
  • Kyoung-Ho Pyo
  • Myung-Ju Ahn

The scientist publishes predominantly in several key oncology and medical journals, including:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Annals of Oncology
  • Lung Cancer

Sample recent papers authored or co-authored include:

  • Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study (2021, The Lancet)
  • Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer (2020, New England Journal of Medicine)
  • Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations (2020, New England Journal of Medicine)
  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer (2020, JAMA Oncology)
  • Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study (2021, Journal of Clinical Oncology)

Best Publications

  • Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana

  • Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    Scott J Antonia;Augusto Villegas;Davey Daniel;David Vicente

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  • Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

    Suresh S Ramalingam;Johan Vansteenkiste;David Planchard;Byoung Chul Cho

  • Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

    Kenneth S Thress;Cloud P Paweletz;Enriqueta Felip;Byoung Chul Cho

  • Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

    Ken Kato;Byoung Chul Cho;Masanobu Takahashi;Morihito Okada

  • Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

    Jong-Mu Sun;Lin Shen;Manish A Shah;Peter Enzinger

  • CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Thanyanan Reungwetwattana;Kazuhiko Nakagawa;Byoung Chul Cho;Manuel Cobo

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Paul K. Paik;Enriqueta Felip;Remi Veillon;Hiroshi Sakai

  • Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

    D Westover;J Zugazagoitia;B C Cho;C M Lovly

  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

    Naiyer A Rizvi;Byoung Chul Cho;Niels Reinmuth;Ki Hyeong Lee

  • Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

    Johan F. Vansteenkiste;Byoung Chul Cho;Tonu Vanakesa;Tommaso De Pas

  • Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    David Planchard;Tae Min Kim;Julien Mazieres;Elisabeth Quoix

  • Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

    Alexander Drilon;Sai Hong Ignatius Ou;Byoung Chul Cho;Dong Wan Kim

  • Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study

    Keunchil Park;Eric B Haura;Natasha B Leighl;Paul L R Mitchell

  • Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

    D. Ross Camidge;Rafal Dziadziuszko;Solange Peters;Tony Mok

  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

    Alexander Drilon;Alexander Drilon;Salvatore Siena;Rafal Dziadziuszko;Fabrice Barlesi

  • Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

    Lecia V. Sequist;Ji Youn Han;Myung Ju Ahn;Byoung Chul Cho

  • Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.

    Jhanelle E. Gray;Augusto Villegas;Davey Daniel;David Vicente

Frequent Co-Authors

Myung-Ju Ahn
Myung-Ju Ahn Sungkyunkwan University
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Robert C. Doebele
Robert C. Doebele University of Colorado Denver
Keunchil Park
Keunchil Park The University of Texas MD Anderson Cancer Center
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medicine but seeking flexible or alternative career paths, a variety of related online degrees can open doors to rewarding roles in healthcare. Many students are drawn to affordability and the convenience of remote learning while securing valuable credentials.

For advanced practice nurses, finding the cheapest dnp program online can allow you to pursue doctoral-level expertise without accumulating significant debt. Meanwhile, those aiming to become pharmacists may consider an online pharmacy degree, which offers a pathway to this high-demand field from virtually anywhere.

Those interested in the digital side of healthcare might pursue a him bachelor's degree online to build knowledge in electronic health records and data management. Alternatively, if you're seeking a quicker entry point into healthcare administration, affordable medical billing and coding programs provide specialized training that can lead to immediate job opportunities.

Exploring these online programs can help you find the best fit for your career goals, lifestyle, and budget, while contributing meaningfully to the healthcare system.

Best Scientists Citing Byoung Chul Cho

Trending Scientists